Menu
GeneBe

rs1800312

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong

The NM_000152.5(GAA):c.2238G>A(p.Trp746Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000434 in 1,613,574 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.000026 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0000021 ( 0 hom. )

Consequence

GAA
NM_000152.5 stop_gained

Scores

5
1
1

Clinical Significance

Pathogenic reviewed by expert panel P:10

Conservation

PhyloP100: 9.45
Variant links:
Genes affected
GAA (HGNC:4065): (alpha glucosidase) This gene encodes lysosomal alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. The encoded preproprotein is proteolytically processed to generate multiple intermediate forms and the mature form of the enzyme. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-80117016-G-A is Pathogenic according to our data. Variant chr17-80117016-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 370904.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr17-80117016-G-A is described in Lovd as [Pathogenic]. Variant chr17-80117016-G-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
GAANM_000152.5 linkuse as main transcriptc.2238G>A p.Trp746Ter stop_gained 16/20 ENST00000302262.8

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
GAAENST00000302262.8 linkuse as main transcriptc.2238G>A p.Trp746Ter stop_gained 16/201 NM_000152.5 P1

Frequencies

GnomAD3 genomes
AF:
0.0000263
AC:
4
AN:
152200
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000797
AC:
2
AN:
250832
Hom.:
0
AF XY:
0.00000737
AC XY:
1
AN XY:
135760
show subpopulations
Gnomad AFR exome
AF:
0.0000617
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000883
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000205
AC:
3
AN:
1461374
Hom.:
0
Cov.:
31
AF XY:
0.00000275
AC XY:
2
AN XY:
727002
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000270
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000263
AC:
4
AN:
152200
Hom.:
0
Cov.:
33
AF XY:
0.0000134
AC XY:
1
AN XY:
74354
show subpopulations
Gnomad4 AFR
AF:
0.0000483
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000294
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.0000264
ExAC
AF:
0.00000824
AC:
1

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Glycogen storage disease, type II Pathogenic:7
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Oct 28, 2020- -
Likely pathogenic, criteria provided, single submitterclinical testingCounsylMay 11, 2016- -
Pathogenic, criteria provided, single submitterclinical testingInvitaeOct 12, 2023This sequence change creates a premature translational stop signal (p.Trp746*) in the GAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). This variant is present in population databases (rs1800312, gnomAD 0.004%). This premature translational stop signal has been observed in individuals with Pompe disease (PMID: 16860134, 22613277, 29122469). ClinVar contains an entry for this variant (Variation ID: 370904). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submittercurationBroad Center for Mendelian Genomics, Broad Institute of MIT and HarvardJan 22, 2020The p.Trp746Ter variant in GAA has been reported in at least 2 Caucasian and 1 Asian individuals with Glycogen Storage Disease II (PMID: 16860134, 22613277, 25741864), and has also been reported likely pathogenic by Counsyl and pathogenic by EGL Genetic Diagnostics, GeneDx, and Invitae in ClinVar (Variation ID: 370904). This variant has been identified in 0.004% (1/24930) of African chromosomes and 0.002% (2/128684) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs1800312). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In vitro functional studies with HEK293 cells transfected with this variant provide some evidence that the p.Trp746Ter variant may impact GAA processing and activity (PMID: 23430493). However, these types of assays may not accurately represent biological function. This nonsense variant leads to a premature termination codon at position 746, which is predicted to lead to a truncated or absent protein. Loss of function of the GAA gene is an established disease mechanism in autosomal recessive Glycogen Storage Disease II. The presence of this variant in combination with a reported pathogenic variant and in an individual with Glycogen Storage Disease II increases the likelihood that the p.Trp746Ter variant is pathogenic (PMID: 22613277). The phenotype of individuals heterozygous for this variant is highly specific for Glycogen Storage Disease II with abnormally low GAA activity detected in an assay of skin fibroblasts (PMID: 16860134, 22613277). One additional pathogenic variant, c.2237G>A (p.Trp746Ter), with the same position and amino acid change has been reported in association with disease (PMID: 26497565, 10206684, 12923862, 16917947, 18429042, 18285536, 21484825, 22980766, 24158270, 22237443, 24169249, 25488666, 25526786, 24269976, 17056254). In summary, this variant meets criteria to be classified as pathogenic for Glycogen Storage Disease II in an autosomal recessive manner based on the predicted impact of the variant and low frequency in the general population. ACMG/AMP Criteria applied: PVS1, PM2, PM3_Supporting, PP4 (Richards 2015). -
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsOct 19, 2022- -
Pathogenic, reviewed by expert panelcurationClinGen Lysosomal Storage Disorder Variant Curation Expert PanelMay 05, 2020This variant, c.2238G>A (p.Trp746Ter), is a nonsense variant, predicted to result in nonsense mediated decay and lack of gene product, meeting PVS1. This is supported by the finding that patients with this variant have no GAA cross-reactive immunological material in protein isolated from cultured skin fibroblasts (i.e. CRIM-negative) (PMID 22252923), as well as functional studies in which there was no measurable GAA activity when the variant was expressed in HEK-293 cells (PMID 23430493). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00004 in the African population, meeting PM2. This variant has been reported in 3 patients who meet the ClinGen LSD VCEP's specifications for PP4. Two of these patients are compound heterozygous for pathogenic variants, either c.-32-13T>G or c.1826dupA (PMIDs 16860134, 22613277, 25741864). The phase is unknown. This data meets PM3. Another patient is compound heterozygous for the variant and c.1843G>A (p.Gly615Arg). This in trans data was used in the assessment of p.Gly615Arg and therefore was not included here in order to avoid circular logic. There is a ClinVar entry for this variant (ClinVar variation ID: 270904, 2 star review status) with 3 submitters classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PM3, PP4 -
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMay 30, 2021Variant summary: GAA c.2238G>A (p.Trp746X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 8e-06 in 250832 control chromosomes. c.2238G>A has been reported in the literature in individuals affected with Glycogen Storage Disease, Type 2 (Pompe Disease) (example, Kishnani_2006, Patel_2012, Mori_2017). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <1% of normal GAA activity as measured following transient expression in HEK293 cells (Nino_2013). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityJun 22, 2023- -
Pathogenic, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Jan 17, 2017- -
Pathogenic, criteria provided, single submitterclinical testingGeneDxDec 09, 2021Published functional studies demonstrate the variant results in reduced GAA activity (Nino et al., 2013); Not observed at a significant frequency in large population cohorts (gnomAD); Nonsense variant predicted to result in nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 26889246, 22613277, 25525159, 23457621, 22252923, 25741864, 26685070, 18519449, 29880332, 29122469, 10206684, 28726123, 33741225, 27655474, 26497565, 16860134, 23430493) -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.50
D
BayesDel_noAF
Pathogenic
0.65
Cadd
Pathogenic
46
Dann
Uncertain
1.0
Eigen
Pathogenic
0.97
Eigen_PC
Pathogenic
0.85
FATHMM_MKL
Pathogenic
0.99
D
MutationTaster
Benign
1.0
A;A
Vest4
0.97
GERP RS
5.1
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs1800312; hg19: chr17-78090815; API